Product Code: TMRGL65504
Sickle Cell Disease Treatment Market - Scope of Report
TMR's report on the global sickle cell disease treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global sickle cell disease treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global sickle cell disease treatment market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the sickle cell disease treatment market.
Market Snapshot |
Market Value in 2023 | US$ 2.7 Bn |
Market Value in 2034 | US$ 17.7 Bn |
CAGR | 18.5% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global sickle cell disease treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global sickle cell disease treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global sickle cell disease treatment market.
The report delves into the competitive landscape of the global sickle cell disease treatment market. Key players operating in the global sickle cell disease treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global sickle cell disease treatment market profiled in this report.
Key Questions Answered in Global sickle cell disease treatment Market Report:
- What is the sales/revenue generated by sickle cell disease treatment across all regions during the forecast period?
- What are the opportunities in the global sickle cell disease treatment market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Sickle Cell Disease Treatment Market - Research Objectives and Research Approach
The comprehensive report on the global sickle cell disease treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global sickle cell disease treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global sickle cell disease treatment market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sickle Cell Disease Treatment Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Sickle Cell Disease Treatment Market Analysis and Forecast, 2020-2034
- 4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
- 5.1. Key Industry Events
- 5.2. PEST Analysis
- 5.3. Pipeline Analysis
- 5.4. Regulatory Scenario by Key Countries/Regions
- 5.5. PORTER's Five Forces Analysis
- 5.6. Reimbursement Scenario by Key Countries
- 5.7. Pricing Analysis
- 5.8. Product/Brand Analysis
- 5.9. Epidemiology of Sickle Cell Disease
- 5.10. Technological Advancements
- 5.11. Supply Chain Analysis
- 5.12. Unmet Needs of the Market
6. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Drug Class
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Drug Class, 2020-2034
- 6.3.1. Antimetabolites
- 6.3.2. Amino Acids
- 6.3.3. NSAIDs
- 6.3.4. Monoclonal Antibodies
- 6.3.5. Others
- 6.4. Market Attractiveness Analysis, by Drug Class
7. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Disease Type
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Disease Type, 2020-2034
- 7.3.1. Hemoglobin SS (HbSS)
- 7.3.2. Hemoglobin SC (HbSC)
- 7.3.3. Hemoglobin (HbS) beta thalassemia
- 7.4. Market Attractiveness Analysis, by Disease Type
8. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Age-Group
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Age-Group, 2020-2034
- 8.3.1. Children
- 8.3.2. Adults
- 8.4. Market Attractiveness Analysis, by Age-Group
9. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Route of Administration
- 9.1. Introduction & Definition
- 9.2. Key Findings/Developments
- 9.3. Market Value Forecast, by Route of Administration, 2020-2034
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.4. Market Attractiveness Analysis, by Route of Administration
10. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Distribution Channel
- 10.1. Introduction & Definition
- 10.2. Key Findings/Developments
- 10.3. Market Value Forecast, by Distribution Channel, 2020-2034
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
- 10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Region
- 11.1. Key Findings
- 11.2. Market Value Forecast, by Region, 2020-2034
- 11.2.1. North America
- 11.2.2. Europe
- 11.2.3. Asia Pacific
- 11.2.4. Latin America
- 11.2.5. Middle East & Africa
- 11.3. Market Attractiveness Analysis, by Region
12. North America Sickle Cell Disease Treatment Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Drug Class, 2020-2034
- 12.2.1. Antimetabolites
- 12.2.2. Amino Acids
- 12.2.3. NSAIDs
- 12.2.4. Monoclonal Antibodies
- 12.2.5. Others
- 12.3. Market Value Forecast, by Disease Type, 2020-2034
- 12.3.1. Hemoglobin SS (HbSS)
- 12.3.2. Hemoglobin SC (HbSC)
- 12.3.3. Hemoglobin (HbS) beta thalassemia
- 12.4. Market Value Forecast, by Age-Group, 2020-2034
- 12.4.1. Children
- 12.4.2. Adults
- 12.5. Market Value Forecast, by Route of Administration, 2020-2034
- 12.5.1. Oral
- 12.5.2. Parenteral
- 12.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 12.6.1. Hospital Pharmacies
- 12.6.2. Retail Pharmacies
- 12.6.3. Online Pharmacies
- 12.7. Market Value Forecast, by Country, 2020-2034
- 12.7.1. U.S.
- 12.7.2. Canada
- 12.8. Market Attractiveness Analysis
- 12.8.1. By Drug Class
- 12.8.2. By Disease Type
- 12.8.3. By Age-Group
- 12.8.4. By Route of Administration
- 12.8.5. By Distribution Channel
- 12.8.6. By Country
13. Europe Sickle Cell Disease Treatment Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Drug Class, 2020-2034
- 13.2.1. Antimetabolites
- 13.2.2. Amino Acids
- 13.2.3. NSAIDs
- 13.2.4. Monoclonal Antibodies
- 13.2.5. Others
- 13.3. Market Value Forecast, by Disease Type, 2020-2034
- 13.3.1. Hemoglobin SS (HbSS)
- 13.3.2. Hemoglobin SC (HbSC)
- 13.3.3. Hemoglobin (HbS) beta thalassemia
- 13.4. Market Value Forecast, by Age-Group, 2020-2034
- 13.4.1. Children
- 13.4.2. Adults
- 13.5. Market Value Forecast, by Route of Administration, 2020-2034
- 13.5.1. Oral
- 13.5.2. Parenteral
- 13.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 13.6.1. Hospital Pharmacies
- 13.6.2. Retail Pharmacies
- 13.6.3. Online Pharmacies
- 13.7. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.7.1. Germany
- 13.7.2. UK
- 13.7.3. France
- 13.7.4. Italy
- 13.7.5. Spain
- 13.7.6. Rest of Europe
- 13.8. Market Attractiveness Analysis
- 13.8.1. By Drug Class
- 13.8.2. By Disease Type
- 13.8.3. By Age-Group
- 13.8.4. By Route of Administration
- 13.8.5. By Distribution Channel
- 13.8.6. By Country/Sub-region
14. Asia Pacific Sickle Cell Disease Treatment Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Drug Class, 2020-2034
- 14.2.1. Antimetabolites
- 14.2.2. Amino Acids
- 14.2.3. NSAIDs
- 14.2.4. Monoclonal Antibodies
- 14.2.5. Others
- 14.3. Market Value Forecast, by Disease Type, 2020-2034
- 14.3.1. Hemoglobin SS (HbSS)
- 14.3.2. Hemoglobin SC (HbSC)
- 14.3.3. Hemoglobin (HbS) beta thalassemia
- 14.4. Market Value Forecast, by Age-Group, 2020-2034
- 14.4.1. Children
- 14.4.2. Adults
- 14.5. Market Value Forecast, by Route of Administration, 2020-2034
- 14.5.1. Oral
- 14.5.2. Parenteral
- 14.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 14.6.1. Hospital Pharmacies
- 14.6.2. Retail Pharmacies
- 14.6.3. Online Pharmacies
- 14.7. Market Value Forecast, by Country/Sub-region, 2020-2034
- 14.7.1. China
- 14.7.2. Japan
- 14.7.3. India
- 14.7.4. Australia & New Zealand
- 14.7.5. Rest of Asia Pacific
- 14.8. Market Attractiveness Analysis
- 14.8.1. By Drug Class
- 14.8.2. By Disease Type
- 14.8.3. By Age-Group
- 14.8.4. By Route of Administration
- 14.8.5. By Distribution Channel
- 14.8.6. By Country/Sub-region
15. Latin America Sickle Cell Disease Treatment Market Analysis and Forecast
- 15.1. Introduction
- 15.2. Market Value Forecast, by Drug Class, 2020-2034
- 15.2.1. Antimetabolites
- 15.2.2. Amino Acids
- 15.2.3. NSAIDs
- 15.2.4. Monoclonal Antibodies
- 15.2.5. Others
- 15.3. Market Value Forecast, by Disease Type, 2020-2034
- 15.3.1. Hemoglobin SS (HbSS)
- 15.3.2. Hemoglobin SC (HbSC)
- 15.3.3. Hemoglobin (HbS) beta thalassemia
- 15.4. Market Value Forecast, by Age-Group, 2020-2034
- 15.4.1. Children
- 15.4.2. Adults
- 15.5. Market Value Forecast, by Route of Administration, 2020-2034
- 15.5.1. Oral
- 15.5.2. Parenteral
- 15.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 15.6.1. Hospital Pharmacies
- 15.6.2. Retail Pharmacies
- 15.6.3. Online Pharmacies
- 15.7. Market Value Forecast, by Country/Sub-region, 2020-2034
- 15.7.1. Brazil
- 15.7.2. Mexico
- 15.7.3. Rest of Latin America
- 15.8. Market Attractiveness Analysis
- 15.8.1. By Drug Class
- 15.8.2. By Disease Type
- 15.8.3. By Age-Group
- 15.8.4. By Route of Administration
- 15.8.5. By Distribution Channel
- 15.8.6. By Country/Sub-region
16. Middle East & Africa Sickle Cell Disease Treatment Market Analysis and Forecast
- 16.1. Introduction
- 16.2. Market Value Forecast, by Drug Class, 2020-2034
- 16.2.1. Antimetabolites
- 16.2.2. Amino Acids
- 16.2.3. NSAIDs
- 16.2.4. Monoclonal Antibodies
- 16.2.5. Others
- 16.3. Market Value Forecast, by Disease Type, 2020-2034
- 16.3.1. Hemoglobin SS (HbSS)
- 16.3.2. Hemoglobin SC (HbSC)
- 16.3.3. Hemoglobin (HbS) beta thalassemia
- 16.4. Market Value Forecast, by Age-Group, 2020-2034
- 16.4.1. Children
- 16.4.2. Adults
- 16.5. Market Value Forecast, by Route of Administration, 2020-2034
- 16.5.1. Oral
- 16.5.2. Parenteral
- 16.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 16.6.1. Hospital Pharmacies
- 16.6.2. Retail Pharmacies
- 16.6.3. Online Pharmacies
- 16.7. Market Value Forecast, by Country/Sub-region, 2020-2034
- 16.7.1. GCC Countries
- 16.7.2. South Africa
- 16.7.3. Rest of Middle East & Africa
- 16.8. Market Attractiveness Analysis
- 16.8.1. By Drug Class
- 16.8.2. By Disease Type
- 16.8.3. By Age-Group
- 16.8.4. By Route of Administration
- 16.8.5. By Distribution Channel
- 16.8.6. By Country/Sub-region
17. Competition Landscape
- 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
- 17.2. Market Share Analysis, by Company (2023)
- 17.3. Company Profiles
- 17.3.1. Bristol-Myers Squibb Company
- 17.3.1.1. Company Overview
- 17.3.1.2. Financial Overview
- 17.3.1.3. Product Portfolio
- 17.3.1.4. Business Strategies
- 17.3.1.5. Recent Developments
- 17.3.2. Novartis AG
- 17.3.2.1. Company Overview
- 17.3.2.2. Financial Overview
- 17.3.2.3. Product Portfolio
- 17.3.2.4. Business Strategies
- 17.3.2.5. Recent Developments
- 17.3.3. Emmaus Medical, Inc.
- 17.3.3.1. Company Overview
- 17.3.3.2. Financial Overview
- 17.3.3.3. Product Portfolio
- 17.3.3.4. Business Strategies
- 17.3.3.5. Recent Developments
- 17.3.4. Bluebird bio Inc.
- 17.3.4.1. Company Overview
- 17.3.4.2. Financial Overview
- 17.3.4.3. Product Portfolio
- 17.3.4.4. Business Strategies
- 17.3.4.5. Recent Developments
- 17.3.5. Pfizer Inc.
- 17.3.5.1. Company Overview
- 17.3.5.2. Financial Overview
- 17.3.5.3. Product Portfolio
- 17.3.5.4. Business Strategies
- 17.3.5.5. Recent Developments
- 17.3.6. CRISPR Therapeutics
- 17.3.6.1. Company Overview
- 17.3.6.2. Financial Overview
- 17.3.6.3. Product Portfolio
- 17.3.6.4. Business Strategies
- 17.3.6.5. Recent Developments
- 17.3.7. F. Hoffmann-La Roche AG
- 17.3.7.1. Company Overview
- 17.3.7.2. Financial Overview
- 17.3.7.3. Product Portfolio
- 17.3.7.4. Business Strategies
- 17.3.7.5. Recent Developments
- 17.3.8. Vertex Pharmaceuticals Incorporated
- 17.3.8.1. Company Overview
- 17.3.8.2. Financial Overview
- 17.3.8.3. Product Portfolio
- 17.3.8.4. Business Strategies
- 17.3.8.5. Recent Developments
- 17.3.9. Agios Pharmaceuticals, Inc.
- 17.3.9.1. Company Overview
- 17.3.9.2. Financial Overview
- 17.3.9.3. Product Portfolio
- 17.3.9.4. Business Strategies
- 17.3.9.5. Recent Developments
- 17.3.10. GlycoMimetics
- 17.3.10.1. Company Overview
- 17.3.10.2. Financial Overview
- 17.3.10.3. Product Portfolio
- 17.3.10.4. Business Strategies
- 17.3.10.5. Recent Developments
- 17.3.11. Graphite Bio, Inc.
- 17.3.11.1. Company Overview
- 17.3.11.2. Financial Overview
- 17.3.11.3. Product Portfolio
- 17.3.11.4. Business Strategies
- 17.3.11.5. Recent Developments
- 17.3.12. Mylan N.V.
- 17.3.12.1. Company Overview
- 17.3.12.2. Financial Overview
- 17.3.12.3. Product Portfolio
- 17.3.12.4. Business Strategies
- 17.3.12.5. Recent Developments
- 17.3.13. Teva Pharmaceutical Industries Ltd.
- 17.3.13.1. Company Overview
- 17.3.13.2. Financial Overview
- 17.3.13.3. Product Portfolio
- 17.3.13.4. Business Strategies
- 17.3.13.5. Recent Developments
- 17.3.14. AstraZeneca
- 17.3.14.1. Company Overview
- 17.3.14.2. Financial Overview
- 17.3.14.3. Product Portfolio
- 17.3.14.4. Business Strategies
- 17.3.14.5. Recent Developments
- 17.3.15. Hikma Pharmaceuticals PLC
- 17.3.15.1. Company Overview
- 17.3.15.2. Financial Overview
- 17.3.15.3. Product Portfolio
- 17.3.15.4. Business Strategies
- 17.3.15.5. Recent Developments
- 17.3.16. Addmedica
- 17.3.16.1. Company Overview
- 17.3.16.2. Financial Overview
- 17.3.16.3. Product Portfolio
- 17.3.16.4. Business Strategies
- 17.3.16.5. Recent Developments